Intrathecal Methotrexate for Gastric Cancer with Leptomeningeal Metastasis
Author Information
Author(s): Xie Wenting, Kang Xun, Huang Sijie, Li Wenbin
Primary Institution: Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Hypothesis
Can intrathecal methotrexate injection improve outcomes for patients with leptomeningeal metastasis from gastric cancer?
Conclusion
Intrathecal methotrexate injection combined treatment offers a potential therapeutic strategy for leptomeningeal metastasis of gastric cancer, improving clinical symptoms and extending survival.
Supporting Evidence
- The average overall survival for the cohort was 7.5 months, which is longer than previously reported.
- A statistically significant decrease in cerebrospinal fluid protein levels was noted after treatment.
- Adverse reactions were mild, with the most common being bone marrow suppression and oral mucosal ulcers.
Takeaway
This study looked at six patients with a rare type of cancer that spreads to the brain and found that a special injection helped them live longer and feel better.
Methodology
The study analyzed six patients who received intrathecal methotrexate injections and compared their symptoms and lab results before and after treatment.
Limitations
The small sample size limits the generalizability of the findings.
Participant Demographics
Four males and two females with a median age of 51 years.
Statistical Information
P-Value
0.040
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website